News
New ASBMT president takes the helm, more hem/onc appointments
Dr. Navneet Majhail will assume the office of ASBMT president at the end of February.
Video
Increased risk of second cancers in mycosis fungoides
LA JOLLA, CALIF. – Researchers found the risk of second malignancy was highest among MF patients aged 30 to 50 years and patients who had tumor...
Video
Cobomarsen shows early promise for treating ATLL
LA JOLLA, CALIF. – A small number of patients experienced disease stabilization or regression on cobomarsen.
News
FDA approves caplacizumab for aTTP
The injection is approved in combination with plasma exchange and immunosuppressive therapy for adults with acquired thrombotic thrombocytopenia...
Video
Cerdulatinib yields ‘encouraging’ results in CTCL, PTCL
LA JOLLA, CALIF. – Some CTCL patients experienced relief from itching after just one pill.
Video
Combo emerges as bridge to transplant in rel/ref PTCL
LA JOLLA, CALIF. – Researchers plan to expand the duvelisib plus romidepsin arm to better understand the occurrence of transaminitis and assess...
News
FDA grants BI-1206 orphan designation for MCL
BI-1206 is under investigation in a phase 1/2a study.
Video
Applying ECHELON-2 results to clinical practice
LA JOLLA, CALIF. – At the annual T-cell Lymphoma Forum, physicians discussed how the ECHELON-2 trial may affect clinical practice.
News
IPH4102 on fast track for Sézary syndrome
The designation is based on results from a phase 1 trial of 35 patients.
News
FDA approves ibrutinib plus obinutuzumab for CLL/SLL
The approval is supported by the phase 3 iLLUMINATE trial.
News
EC approves blinatumomab for MRD-positive BCP-ALL
The approval was based on data from the phase 2 BLAST trial.
News
Umbralisib gains FDA breakthrough designation for MZL
Umbralisib is a PI3K-delta inhibitor being developed for the treatment of adults with marginal zone lymphoma.
News
Combo treatment may improve quality of life in CTCL
LA JOLLA, CALIF. – In a small study, patients experienced relief from pruritus after just one cycle of treatment with brentuximab vedotin plus...
News
Are single agents better than chemo for relapsed/refractory PTCL?
LA JOLLA, CALIF. – Complete response rates and survival times were better among patients who received single-agent therapy.
Video
Four-drug combo shows durable responses in relapsed/refractory lymphomas
LA JOLLA, CALIF. – The phase 1 study tested the addition of a histone deacetylase inhibitor to platinum-based chemotherapy.